AseBio

#NewAseBioMember | “AseBio, for our small biotech, is a platform that offers a multitude of benefits”

Meet Telomere Therapeutics, our new member. We spoke with Ana Margarita Maldonado, CMC & Regulatory Manager.

Ana Margarita Maldonado, CMC & Regulatory Manager de Telomere Therapeutics
AseBio
Corporate

AseBio. What does your company's work bring to the table and what is its strength?

Ana Margarita Maldonado. Our company’s work brings hope to idiopathic pulmonary fibrosis patients and their families since, to date, there is no cure for this devastating rare disease. It also brings an innovative approach to tackle the clear unmet medical need it represents for clinicians. The company’s most valuable asset is its team and their patient dedication, its know-how, and its first-in-class approach, generated during many years of the scientific founders’ research.

AseBio. What is AseBio for you?

Ana Margarita Maldonado. AseBio, for our small biotech, is a platform that offers a multitude of benefits. As a relatively new entrant into the biotech industry, joining AseBio provides us with invaluable access to a network of established companies, experts, and resources.

AseBio. When did you first hear about AseBio?

Ana Margarita Maldonado. When I started working in scientific research, as well as my colleagues.

AseBio. What do you expect from being part of an association like AseBio?

Ana Margarita Maldonado. We anticipate building strong relationships with other biotech companies, industry experts, and potential partners. We hope it will help actively advocate for the interests of the biotech sector to policymakers and regulators. Finally, we expect access to training programs, workshops, and conferences that will enhance our team's skills and knowledge.

AseBio. What is the biggest challenge facing the biotech sector (or your company)?

Ana Margarita Maldonado. One of the most significant challenges facing the biotech sector, particularly small biotechs, is access to funding. Securing adequate funding to support research, development, and commercialization can be a major hurdle. This is especially true for early-stage companies like us.

Additionally, regulatory hurdles can pose a significant challenge. The process of obtaining regulatory approvals for new products can be lengthy, complex, and expensive. These delays can impact time-to-market and ultimately hindering commercial success.

For our specific company, a key challenge is scaling up operations. As we transition from research and development to commercialization, we will need to establish efficient manufacturing processes. This can be a capital-intensive endeavor.